Four leading Business Names in 2019; BWX, IPD, LOV, CCX

healthcare stocks

Australian Stock Exchange (ASX), a leading stock exchange houses over 2,185 listed entities in its premises. Investors have a wide variety of businesses to choose from, among even wider industries of the country.

In this article, we focus on household & personal care products, health care equipment, & premium retailers. During moderating growth rates among advanced economies, sending signals of a slowdown backed by moderating manufacturing numbers.

Essentials appear more desirable at this point of time, due to the fact that these industries deliver necessary goods & services, which is relatively less-prone to cyclical downside risks amid moderating growth rates in a wider setting.

It is also equally sensible that the downside risks posed by any company are idiosyncratic. However, on a broader perspective, systematic risks in the similar industry remain equally pervasive to the companies hosted in an industry.

Let us go through such stocks in details:

BWX Limited (ASX: BWX)

BWX plies in the branded skin & hair care products trade, with a strong focus on the beauty and personal care’s natural segment. It is a vertically integrated developer, manufacturer, distributor & marketer of these products.

As on 08 October 19, at a market capitalisation of $514.39 million, it is an emerging company, recognised in the S&P/ASX Emerging Companies Index. Despite resonating declining profitability in its full year ended 30 June this year, the market is still upbeat on the stock with 3-month return of +100.00%, trading at a PE multiple of 53.770x.

BWX LimitedMarket Opportunity (Source: BWX’s FY19 Financial Results Presentation)

Valuation appears higher compared to its peers, as such Blackmores Limited (ASX: BKL), trading at a PE multiple of 26.870x, probably to due declining profitability, leading to shrinking EPS amid an increase in the market price.

A reasonable question arises here – what has led to declining profits?

A closer look at the consolidated financials for the year suggests, declining gross profit margins, among others. Cost of sales increased to $71.51 million compared to $60.41 million in the previous year. Relatively, sales revenue has grown slightly to $149.51 million from $148.71 million in the previous year; however, increasing on sequential terms over the half-year period.

As a growing company, it appears reasonable for it to pursue aggressive marketing strategies, leading to higher expenditure in marketing, selling and distribution, research and development along with the cost of sales.

On 08 October 2019, BWX was trading at $4.040 (at AEST 1:13 PM), down by 2.415%.

ImpediMed Limited (ASX: IPD)

ImpediMed designs & manufactures medical devices for non-invasive clinical assessment, assessing tissue compositions, and fluid status. Its devices leverage bioimpedance spectroscopy (BIS) technologies, and its product line-up includes FDA cleared and CE Marked medical devices.

In its full year report ended 30 June 2019, the total revenue was up by 25% over the previous year to $4.2 million compared to $3.3 million in FY2018. Revenue from SOZO® for FY 2019 was up by 229% to $2.3 million against $0.7 million.

ImpediMed LimitedSOZO® (Source: IPD Annual Report 30 June 2019)

Some more attributes of rapid growth are noticeable in the FY 20 guidance of the company, having an attractive reporting revenue target of $7 million to $10 million. In addition, among non-IFRS metrics, IPD expects Annual Recurring Revenue of $6.0 million to $10.0 million, and a Contracted Revenue Pipeline of $18.0 million to $24.0 million by end FY20.

Investing in health care companies needs high patience, as the processes making these organisations larger and competitive takes times, particularly healthcare. It is due to the fact that the goods & services delivered by this industry are highly complex and experimental in nature. However, these goods & services pose a robust demand, as healthcare being an essential part of human life.

As such, IPD had contracted its losses over the year, coming down to a total net loss of $24.12 million from $27.38 million in the previous year.

On 8 October 2019, IPD was trading flat $0.165 (at AEST 1:26 PM).

Lovisa Holdings Limited (ASX: LOV)

In a setting where retailers have been facing margin erosion, Lovisa Holdings has expanded its gross margin, attributing to effective management techniques. The company sells in fifteen countries, leveraging daily inventory monitoring software and airfreight to move products across the global supply chain.

Lovisa Holdings LimitedOutlook (Source: LOV’s Full Year Results Presentation)

According to its full-year results ended 30 June 2019, the company posted a net profit after tax of $37 million, an increase of 3% from $35.95 million in the previous year. The company achieved this result when same-store sales were down by 0.5%. Conversely, it added net 64 stores across the globe, and its gross margin increased due to better inventory management & stronger USD hedge rate during the period.

At the year-end, the company was operating 390 retail stores, and 36 franchise stores across the globe, leveraging them to achieve a reported revenue of $250.3 million, depicting a 15.3% increase over the prior year. Further, the gross profit increased by 16% to $201.4 million from 173.63 million in the previous year.

Mr Brett Blundy is the Non- Executive Chairman of the company. In his letter for the Annual Report, it was stated that the company is actively pursuing customer-led demand and capitalised on the arising opportunity for piercings in the USA.

The company had learned to open up its piercing business, following the extension of its capabilities in international markets that led to an emergence of a new customer need. He also said that the status quo should be continually challenged, which appears reasonable in our aggressively dynamic world with a variety of customer needs.

On 8 October 2019, LOV was trading at $12.88 (at AEST 1:35 PM) up by 0.468%.

City Chic Collective Limited (ASX: CCX)

CCX operates in the women fashion retail segment in Australia, New Zealand, USA, Germany & the UK. Its position in the plus size women market seems appealing to the investors, with 104 stores in ANZ, and growing partner business in Europe & North America.

In July 2018, the group had sold five of its brand to Noni B Limited (ASX: NBL) for a cash consideration of $31 million. In its full year ended 30 June 2019, CCX recorded a net profit after tax from continuing operations of $14.3 million compared to $15 million in the previous year.

City Chic Collective LimitedCCX (Source: CCX’s FY19 Full Year Results Presentation)

Besides, the net profit after tax for the group was $16 million compared to a loss of $9.3 million in the previous year. Sales of revenue of the group from continuing operation for the period was $148.4 million compared to $131.9 million in the previous year.

On 4 October 2019, CCX reported that it was a successful bidder for the e-commerce assets of Avenue Stores, LLC – a US-based retailer. The company has been the winning bidder with an offer price of USD 16.5 million. Further, the transaction is subject to the court hearing by the US Bankruptcy Court in Delaware, USA.

On 8 October 2019, CCX was trading at $2.830 (at AEST 1:39 PM), up by 1.071%.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice. 

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report